Literature summary for 2.7.1.91 extracted from

Sauer, L.; Nunes, J.; Salunkhe, V.; Skalska, L.; Kohama, T.; Cuvillier, O.; Waxman, J.; Pchejetski, D.
Sphingosine kinase 1 inhibition sensitizes hormone-resistant prostate cancer to docetaxel (2009), Int. J. Cancer, 125, 2728-2736.

Search for more literature for 2.7.1.91

Application

Application	Comment	Organism
medicine	SphK1 inhibition by docetaxel is a two-step process involving an initial loss of enzyme activity followed by a decrease in SphK1 gene expression. Both pharmacological and siRNA-mediated SphK1 inhibition leads to a four-fold decrease in the docetaxel IC50 dose	Homo sapiens

Inhibitors

Inhibitors	Comment	Organism	Structure
docetaxel	SphK1 inhibition by docetaxel is a two-step process involving an initial loss of enzyme activity followed by a decrease in SphK1 gene expression. Both pharmacological and siRNA-mediated SphK1 inhibition leads to a four-fold decrease in the docetaxel IC50 dose	Homo sapiens

Organism

Organism	UniProt	Comment	Textmining
Homo sapiens	-	-	-

Source Tissue

Source Tissue	Comment	Organism	Textmining
DU-145 cell	-	Homo sapiens	-
PC-3 cell	-	Homo sapiens	-

Expression

Organism	Comment	Expression
Homo sapiens	SphK1 inhibition by docetaxel is a two-step process involving an initial loss of enzyme activity followed by a decrease in SphK1 gene expression. Both pharmacological and siRNA-mediated SphK1 inhibition leads to a four-fold decrease in the docetaxel IC50 dose	down

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)